Ultra Body Academy

Selank 5 mg Dosage Protocol

Table of Contents

What is Selank?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) modeled after the naturally occurring immunomodulatory peptide tuftsin. Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, it acts as a synthetic anxiolytic and nootropic signaling agent.

 

Unlike traditional anxiolytics (e.g., benzodiazepines), Selank modulates central nervous system pathways—including $GABA_A$ receptor complex activity, enkephalin stability, and brain-derived neurotrophic factor (BDNF) expression—without sedation, muscle relaxation, or cognitive impairment.

Primary Research Areas

  • Anxiety & Stress Response: Studied in models of generalized anxiety disorder (GAD), neurasthenia, and stress-induced anxiety.
  • Nootropic & Cognitive Function: Evaluated for memory consolidation, learning enhancement, and executive focus under mental fatigue.
  • Neuroprotection & Neuroplasticity: Investigated for upregulating BDNF and stabilizing endogenous leu-enkephalins by inhibiting enkephalin-degrading enzymes.
  • Immunomodulation: Retains structural elements of tuftsin to influence immune signaling, interleukin expression, and peripheral inflammatory markers.

Intranasal Reconstitution & Calculation Guide

Human clinical trials primarily evaluate Selank via intranasal administration (drops or metered sprays). To convert a 5 mg (5,000 mcg) lyophilized vial into an intranasal research solution, the peptide is dissolved in a sterile vehicle (e.g., sterile 0.9% sodium chloride or purified water) and transferred to a metered nasal spray actuator bottle.

 

Standard Device Output: Calculations assume a standard metered nasal pump verified to release 0.10 mL per full actuation (spray).

Dosing & Spray Concentration Options

Target Final Volume
Vehicle Added
Final Solution Concentration
5.0 mL
~2.0 mL (after 3.0 mL initial vial reconstitution)
1,000 mcg/mL (1 mg/mL)
10.0 mL
~7.0 mL (after 3.0 mL initial vial reconstitution)
500 mcg/mL (0.5 mg/mL)

Reconstitution Protocol

  1. Aseptic Preparation
    Sanitize the rubber septum of the 5 mg Selank vial and the top of the sterile vehicle container with 70% isopropyl alcohol wipes. Allow to air-dry completely.
  2. Initial Reconstitution
    Using a sterile syringe, draw 3.0 mL of sterile saline or purified water. Direct the liquid slowly down the glass side wall of the Selank vial. Gently swirl (do not shake) until the powder is fully dissolved into a clear liquid.
  3. Transfer to Actuator Bottle
    Draw the entire reconstituted 3.0 mL solution from the vial using a sterile syringe and transfer it into a sterile 5 mL or 10 mL metered nasal spray actuator bottle.
  4. Final Dilution Step
    Add additional sterile vehicle to reach the target measured final volume: For 5.0 mL Total Volume: Add approximately 2.0 mL additional vehicle. For 10.0 mL Total Volume: Add approximately 7.0 mL additional vehicle.
  5. Device Priming & Labeling
    Attach the metered pump firmly. Label the bottle with Peptide Name, Total Mass (5 mg), Final Volume, Concentration (mcg/mL), and Preparation Date. Prime the pump according to manufacturer guidelines (usually 2–4 test actuations) before logging experimental spray outputs.

Actuator Mathematical Conversions

To map your custom preparation against published human literature amounts, apply these mathematical actuator conversions. Note that fractional sprays are theoretical calculations only, as a metered device can only express a complete 0.10 mL stroke.

  • 300 mcg Research Target: Requires 1.5 theoretical sprays using the 5 mL volume setup, or exactly 3 complete sprays using the 10 mL volume setup.
  • 900 mcg Research Target: Requires 4.5 theoretical sprays using the 5 mL volume setup, or exactly 9 complete sprays using the 10 mL volume setup.
  • 2,700 mcg Research Target: Requires 13.5 theoretical sprays using the 5 mL volume setup, or exactly 27 complete sprays using the 10 mL volume setup.

Storage

  • Lyophilized Powder (Before Mix): Store at 2–8°C (36–46°F) under dark, moisture-free conditions. For long-term preservation spanning several months, keep stored at −20°C (−4°F).
  • Reconstituted Custom Solution (After Mix): Store continuously refrigerated at 2–8°C (36–46°F) and protect from light exposure. If using an unpreserved saline vehicle, utilize the solution within 10 to 14 days to maintain sterility.
  • Note on Registered Equivalents: Commercial, pre-formulated 0.15% Selank drop solutions containing stabilizers permit a temporary 15-day storage window up to 25°C (77°F), but unpreserved custom research batches should always remain strictly refrigerated. Never expose the peptide to freezing temperatures once mixed.

Research Controls & Technical Notes

  • Pump Variability: Actuator outputs are not universally identical. Standard commercial pumps can vary anywhere from 0.025 mL to 0.20 mL per stroke. Verify your specific hardware specifications prior to calculating final metrics.
  • Delivery Performance Variables: In alignment with standard regulatory guidance for nasal spray delivery systems, factors such as bottle orientation (always hold upright), stroke force, priming consistency, and residual tail-off volume near bottle exhaustion must be tracked and logged as active experimental variables.
  • Observed Effects & Tolerance: In human trials, transient adverse effects are rare but can include brief altered or unpleasant taste sensations and localized nasal membrane sensitivity. Selank does not display signs of habituation, cognitive slowing, or typical withdrawal symptoms in clinical literature.

Regulatory Compliance Disclaimer

IMPORTANT NOTICE: This product is engineered and distributed exclusively for in-vitro laboratory testing and scientific research applications. It is strictly NOT a medicine, drug, or dietary supplement and is not intended for human consumption or veterinary use. This compound has not been evaluated or approved by the MHRA, FDA, or EMA. Any use outside of legitimate, controlled laboratory environments is strictly prohibited. The purchaser assumes all liability for the safe handling and legal compliance of this material.

References

— Comparative clinical study of Selank in adults with generalized anxiety disorder and neurasthenia: evaluation of intranasal dosing regimen and therapeutic outcomes
— Clinical evaluation of Selank in generalized anxiety disorder: intranasal dosing strategies and neurophysiological response patterns
— Functional neuroimaging study of acute intranasal Selank administration in healthy adult volunteers
— Manufacturer prescribing information: 0.15% Selank nasal formulation, composition, administration instructions, and storage recommendations
— Nasal spray drug products: guidance on device performance, dose uniformity, priming, and quality considerations
Scroll to Top